Novo Nordisk, a global leader in diabetes and obesity care, announced on Monday that its investigational weight loss treatment, CagriSema,…
Read More
Novo Nordisk’s triple agonist delivers up to 19.7% average weight loss in Phase 2 trial
Novo Nordisk, a global leader in diabetes and obesity care, announced a significant advancement in its weight management pipeline with…
Read More
Closing the Information Gap: ETH Zurich Team Integrates Function and Binding in One Drug Screening Assay
A groundbreaking collaborative effort between researchers at ETH Zurich and Karolinska Institutet has culminated in the development of a novel…
Read More
Can live cell dynamics fix drug discovery’s efficacy problem?
The pharmaceutical industry faces a profound and escalating crisis marked by soaring costs, protracted timelines, and persistently high failure rates…
Read More
From list price to net price: How finance leaders decode real drug costs
In the intricate landscape of the healthcare industry, discussions surrounding drug pricing frequently commence and conclude with the list price.…
Read MoreYOU MAY HAVE MISSED
